The Global Myasthenia Gravis Treatment Market is poised to register a CAGR of 7.5% during the forecast period 2022 to 2028.
The global myasthenia gravis treatment market is expanding rapidly and will continue to expand in the coming years. Myasthenia gravis is a disorder that causes the skeletal muscles of the body to weaken. In myasthenia gravis, the immune system disrupts nerve impulse transmission to muscles by producing antibodies that bind to proteins involved in nerve signal transmission. Normally, antibodies bind to specific foreign particles and germs, marking them for destruction, but in myasthenia gravis, the antibody attacks a normal human protein. In most cases, the antibody attacks a protein called acetylcholine receptor (AChR), while in others, the antibodies attack a protein called muscle-specific kinase (MuSK). In both cases, the abnormal antibodies reduce the amount of AChR that is available. Consistent R&D activities are expected to drive the growth of the myasthenia gravis treatment market. For example, Alexion Pharmaceuticals, Inc. received approval from the US Food and Drug Administration in October 2017 for Soliris, which contains eculizumab as an active component. This medication is used to treat antibody-positive generalised myasthenia gravis, as well as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Furthermore, the growing number of clinical trials for the treatment of myasthenia gravis is expected to drive the growth of the myasthenia gravis treatment market. In December 2017, Novartis AG, for example, began a phase II clinical trial of CFZ533 for the treatment of severe myasthenia gravis. The primary function of CFZ533 is to modify immune response by deactivating white blood cells. As a result, it is expected to aid in the treatment and management of severe myasthenia gravis. ARGX-113 is also being studied in a clinical phase III study by Argenx BVBA for the treatment of generalised myasthenia gravis. ARGX-113, also known as Efgartigimod, is given intravenously.
The astute research report on Myasthenia Gravis Treatment market provides intricate details for analyzing appropriate parameters and valuable insights. The report offers extensive information about this business to help bring forth the growth potential of the market across various segments and provides the clients with a comprehensive analysis of factors like market size, market growth trends, competitive landscape, product utilization, regional growth prospects, and application potential, etc. The data provided in the report has been gathered from a wide variety of sources by using primary and secondary research. This Myasthenia Gravis Treatment research report also provides crucial insights into consumer behaviour, brand positioning, pricing analysis, and key player strategies. The market overview included in the Myasthenia Gravis Treatment research report incorporates critical factors procured from industry analysts, prominent players as well as trade and industrial organizations.
The report on Myasthenia Gravis Treatment market offers up-to-date information on the factors impeding the market growth which shall provide vendors with crucial insights into understanding the market dynamics thereby aiding the clients to sketch out a better business strategy. These factors will help them identify market growth opportunities. Furthermore, FutureWise research analysts provide timely assistance to their customers in understanding eccentric market parameters more effectively thereby leading to better decision-making.
Get a Sample of the Myasthenia Gravis Treatment Market Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=11533&page=requestsample
The Myasthenia Gravis Treatment market research report is segmented – by drug class, by distribution channel, and by region. It also consists of insights regarding the revenue value and sales volume during the forecasted timeframe of 2022 to 2028.
Myasthenia Gravis Treatment Market Segmentation:
By Drug Class
Cholinesterase Inhibitors
Corticosteroids
Immunosuppressants
Other Drug Classes
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Platform
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Myasthenia Gravis Treatment Market Regional Analysis:
The report provides a complete evaluation of the potential amplification of the Myasthenia Gravis Treatment Market in pivotal geographic regions such as North America, Asia Pacific, Europe, Latin America and Middle East & Africa.
Competitive Landscape:
Some of the key market players are
AbbVie, Inc.
Alexion Pharmaceutical, Inc.
Amneal Pharmaceuticals, Inc.
Argenx SE
Astellas Pharma, Inc.
Avadel Pharmaceuticals PLC
Bausch Health Companies Inc.
Baxter International, Inc.
CSL Behring
CuraVac, Inc.
F. Hoffmann-La Roche, Ltd.
GlaxoSmithKline plc
Grifols SA
Immunovant, Inc.
Mitsubishi Tanabe Pharma Corp.
Novartis AG
RA Pharmaceuticals, Inc.
Takeda Pharmaceutical Co., Ltd.
UCB Pharma
Valeant Pharmaceuticals International, Inc.
FutureWise Key Takeaways:
Growth prospects
SWOT analysis
Key market trends
Key data-points affecting market growth
Objectives of the Study:
To provide an extensive analysis of the global Myasthenia Gravis Treatment market by drug class, by distribution channel, and by region
To carter complex data and information on the characteristics influencing the market growth (drivers, restraints, opportunities, and industry-specific restraints)
To predict and assess micro-markets and the overall market
To anticipate the market size, in key geographical regions (along with countries)— North America, Europe, Asia Pacific, Latin America and the Middle East and Africa
To estimate and inspect competitive landscape mapping- technological advancements, product launches, mergers and expansions
Flexible Delivery Model:
Our delivery model is flexible, so you can suggest changes to the content/scope as per your requirement
With purchase of any license of the report the customization Mobility Care offered is free of charge
You can directly forward your requirements/changes to the current table of content to: sales@futurewiseresearch.com
About FutureWise Market Research:
We specialize in high-growth niche market research, offering flexibility, agility, and customized solutions for our clients. By providing our clients with market insights and consulting services, we ensure they stay on top of their industries for years to come.
FutureWise Market Research
Vinay T – Head of Business Development
Email: sales@futurewiseresearch.com
UK: +44 141 628 9353 | USA: +1 347 709 4931
Website: www.futurewiseresearch.com
